Marc Penn, 2013 Symposium, Trials and Tribulations of Assessing CVD Risk in 2013

Cleveland HeartLab News

Marc Penn, MD, PhD, FACC discusses the Trials and Tribulations of Assessing CVD Risk in 2013 at the 2013 Cleveland HeartLab Symposium in Dallas, Texas.

Listen as Dr. Marc Penn reviews strategies for defining cardiovascular risk based on novel biomarker tests.  To open, Dr. Penn reviews recent literature that supports the lowering of hsCRP to reduce cardiovascular risk and initial findings from the 2008 JUPITER Trial.  Dr. Penn goes on to review how the use of specific inflammatory biomarkers can risk stratify patients based on their known pathophysiology, and ultimately guide treatment strategies to reduce cardiovascular risk.